InterventionsHuman trial
Amycretin, a Novel, Unimolecular GLP-1 and Amylin Receptor Agonist—Results of a Phase 1b/2a Clinical Trial
ADA Scientific Sessions 2025 Abstract
The paper
DAHL K, ADELBORG K, DEY S et al.
ADA Scientific Sessions 2025 Abstract · 13 Jun 2025
Presented at ADA Scientific Sessions 2025 · Late-breaking 2002-LB